Evidence map›Paper›PMID 40886193›Full record

ArticleCancer immunology, immunotherapy : CII2025

Interleukin 15 (IL15)-based near-infrared photoimmunotherapy.

Motofumi Suzuki, Aki Furusawa, Hiroshi Yamamoto, Makoto Kano, Miyu Kano, Seiichiro Takao, Shuhei Okuyama, Peter L Choyke, Hisataka Kobayashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Motofumi SuzukiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.ORCID https://orcid.org/0000-0003-0348-9422
Aki FurusawaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.ORCID https://orcid.org/0000-0002-1339-4219
Hiroshi YamamotoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Makoto KanoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Miyu KanoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Seiichiro TakaoMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.ORCID https://orcid.org/0000-0002-7920-0763
Shuhei OkuyamaMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Peter L ChoykeMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.ORCID https://orcid.org/0000-0003-1086-8826
Hisataka KobayashiMolecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA. kobayash@mail.nih.gov.ORCID https://orcid.org/0000-0003-1019-4112

Funding

Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
CCR NIH HHS ZIA BC 011513
6 · The paper itself

Abstract

Near-infrared photoimmunotherapy (NIR-PIT) is a highly selective cancer therapy based on a targeted monoclonal antibody conjugated to phthalocyanine-based photoabsorber, IRDye700DX (IR700). Following injection, near-infrared light activates the conjugate causing direct cytotoxicity and immunogenic cell death. The high selectivity of NIR-PIT is traditionally based on the binding of a monoclonal antibody to its target thus bringing the photoabsorber, IR700, in close proximity to the cell membrane at the time of light exposure. However, other targeting moieties can be used and in the current study, interleukin-15 (IL15) is conjugated with IR700 to enable NIR-PIT. IL15-IR700 quickly bound to the cellular membrane of MC38 HIL15Rα cells that are transfected with human IL15 receptor alpha. NIR-PIT induced characteristic morphological changes accompanied by a significant decrease of cellular viability. Intratumoral injection of IL15-IR700 resulted in longer retention of the conjugate in the tumor compared to the intravenous injection. NIR-PIT with intratumoral IL15-IR700 significantly suppressed tumor growth, induced necrosis-like changes in tumor tissue, and stimulated host immune response. This study revealed that cytokine-based NIR-PIT is a potential therapeutic strategy for treating solid cancer.

Indexed as

ImmunotherapyInterleukin-15NeoplasmsPhototherapyAnimalsAntibodies, MonoclonalCell Line, TumorFemaleHumansIndolesInfrared RaysIsoindolesMiceMice, Inbred BALB CXenograft Model Antitumor AssaysAntibodies, MonoclonalIndolesInterleukin-15IsoindolesImmunogenic cell deathInterleukin-15Near-infrared photoimmunotherapyTumor treatment

Identifiers

PMID40886193
PMCPMC12399473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.